Solutions To Innovate Your Transition From Clinical To Commercialisation
In this exclusive interview conducted ahead of this year’s Cell and Gene Therapy Manufacturing conference, Simon Briggs, Product Steward Cell and Gene Therapy Unit – Kymriah, C&G Technical Operations, Novartis shares his views on how to successfully achieve commercialisation.
With increased pressures on process scalability and regulatory compliance, Simon Briggs highlights some of the challenges and solutions Novartis have faced when transitioning from clinical to commercialisation.
Download our latest interview to get the answers to the following questions:
- Where is Novartis now in terms of a worldwide launch of Kymriah? What are your next priorities?
- Looking back on the transition between clinical and commercial, did your strategy for commercialisation meet the realities you were expecting? And if not, why don’t you think they did?
- You mentioned there are a few success factors to achieving commercialisation. Are there any other critical success factors that you’d like to highlight?
- What would you say about the current market paradigm for sustainable autologous therapies in terms of manufacturing capabilities and routes to commercialisation?
Please note: That all fields marked with an asterisk (*) are required.